Transthyretin Amyloidosis (ATTR) for Professionals

Participation in activities of daily life can be challenging for those with ATTR-CM, a restrictive cardiomyopathy produced by extracellular deposition of transthyretin.

Geographic and racial healthcare disparities add to the burden of disease. Shared decision making and early detection with readily available noninvasive tests, among other strategies, are essential as therapy for ATTR-CM.

Videos On Demand

Developing an Amyloidosis Center of Excellence: Path to Success and Overcoming Challenges
This is the third and final webinar in the series and discusses steps to develop a center of excellence to provide leadership, best practices, support and/or training of health care professionals within a multidisciplinary team environment to improve the quality of care for cardiac amyloidosis patients as well as challenges that may occur.
Breaking Down Barriers: Defining and Addressing Healthcare Disparities in ATTR-CM
This is the second webinar in the series. ATTR-CM disproportionately affects black people, a medically underserved population. In this webinar clinicians explore how addressing geographic and racial healthcare disparities can make meaningful differences. Hypertension and other symptoms may confound accurate, timely diagnosis and treatment for many individuals with ATTR-CM. Watch S. Carolina Masri, Kevin Alexander and Nancy Albert discuss practical steps clinicians can take in breaking down barriers for those with ATTR-CM. CE and MOC Credits Available. Approved for 1.0 AAFP Prescribed Credit. Free Webinar.
Empowering Your Patients to Understand ATTR-CM
In this first of a 3-part series, watch Nancy M. Albert and Katherine E. Di Palo join moderator Kevin Alexander in discussing ways to empower patients to recognize ATTR-CM and share in decision-making about diagnostic and treatment options. CE/ABIM MOC credit available. Approved for 1.0 AAFP Prescribed/Elective credits. Free webinar.

Recognize the Complexities of Transthyretin Amyloidosis (ATTR amyloidosis)

The clinical presentation of ATTR may be hidden in plain sight. In these continuing education activities explore the varied clinical presentations of amyloidosis in different organ systems including the heart, nervous system, gastro-intestinal tract, and kidneys. Get the facts from an expert panel on how to recognize and treat the complexities of this progressive, degenerative, and multisystemic disorder.


Extra-Cardiac Clues to Amyloidosis

This podcast will offer guidance on early identification of non-cardiac manifestations of amyloidosis from the perspective of the Gastrointestinal and Neurology clinical communities.

Future Directions and Areas of Uncertainty for ATTR: Where will we be in the next decade?

This podcast discusses areas of uncertainty and future directions in the screening, diagnosis, prognostic assessment, and management of ATTR Cardiac Amyloidosis. We will also discuss the effect of social determinants of health on access to effective diagnosis and treatment of ATTR Cardiac Amyloidosis and determine ways this can be improved. The podcast will also discuss gaps in knowledge about effective tools to follow disease progression in ATTR Cardiac Amyloidosis.

Unraveling the Mysteries of ATTR - Exploring Diagnostic Challenges, Laboratory Tests, Barriers, and Treatment Breakthroughs

Learn more in this podcast on the correct diagnosis of ATTR and how to devise a treatment plan for your patients. Experts will also discuss engaging in evaluative strategies for early detection through genetic testing by identifying genetic variants that are pertinent to the population we serve here in the United States especially that leads to hereditary ATTR.

Diagnostic Imaging Strategies for Cardiac Amyloidosis

This podcast will focus on multimodality cardiac imaging approaches and the application of diagnostic findings which contribute to an accurate diagnosis of ATTR-CM, specifically in differentiating ATTR-CA from AL-CA, and how to determine treatment options.

Pathophysiology and Clinical Features of TTR Cardiac Amyloidosis: No Longer a “Rare” Disease and Still Underdiagnosed

Health Care Practitioners (HCPs) have a pivotal role in ensuring the right patients get the right treatment. Patients living with ATTR-CM have new treatment options that have recently become available. In order to accurately diagnose and treat symptoms unique to the ATTR-CM patient, HCPs need to be aware of the application of guideline-based systematic, multimodal imaging and clinical diagnostics related to ATTR-CM. This podcast will highlight the latest terminology, treatments and guidelines for this no longer rare disease.

Pharmacotherapy for Cardiac Amyloidosis

In this podcast, experts will discuss the latest pharmacologic recommendations and their evolution in the treatment of cardiac amyloidosis. They will delineate the different potential therapeutic targets for the pharmacotherapy of cardiac amyloidosis including TTR silencing, stabilization, and disruption.